JP2008545616A - ジスキネジーの阻害または治療 - Google Patents

ジスキネジーの阻害または治療 Download PDF

Info

Publication number
JP2008545616A
JP2008545616A JP2007555704A JP2007555704A JP2008545616A JP 2008545616 A JP2008545616 A JP 2008545616A JP 2007555704 A JP2007555704 A JP 2007555704A JP 2007555704 A JP2007555704 A JP 2007555704A JP 2008545616 A JP2008545616 A JP 2008545616A
Authority
JP
Japan
Prior art keywords
dopa
alkyl
inhibitor
dyskinesia
dopamine agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007555704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545616A5 (https=
Inventor
イルヴァニ，マーモード
ジェンナー，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Cambridge Ltd
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0503540A external-priority patent/GB0503540D0/en
Priority claimed from GB0508843A external-priority patent/GB0508843D0/en
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of JP2008545616A publication Critical patent/JP2008545616A/ja
Publication of JP2008545616A5 publication Critical patent/JP2008545616A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007555704A 2005-02-21 2006-02-20 ジスキネジーの阻害または治療 Withdrawn JP2008545616A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0503540A GB0503540D0 (en) 2005-02-21 2005-02-21 Inhibition or treatment of dyskinesia
GB0508843A GB0508843D0 (en) 2005-04-29 2005-04-29 Inhibition or treatment of dyskinesia
PCT/GB2006/000583 WO2006087577A2 (en) 2005-02-21 2006-02-20 Inhibition or treatment of dyskinesia

Publications (2)

Publication Number Publication Date
JP2008545616A true JP2008545616A (ja) 2008-12-18
JP2008545616A5 JP2008545616A5 (https=) 2009-04-09

Family

ID=36691702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007555704A Withdrawn JP2008545616A (ja) 2005-02-21 2006-02-20 ジスキネジーの阻害または治療

Country Status (6)

Country Link
US (1) US20080070952A1 (https=)
EP (1) EP1850838A2 (https=)
JP (1) JP2008545616A (https=)
CA (1) CA2598484A1 (https=)
SG (1) SG160342A1 (https=)
WO (1) WO2006087577A2 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT891332E (pt) * 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
JP3505189B2 (ja) * 1997-02-10 2004-03-08 ファイザー・プロダクツ・インク ２−アミノ−６−（２−置換−４−フェノキシ）−置換ピリジン
WO1998048826A1 (en) * 1997-04-30 1998-11-05 Northwestern University Inhibition of nitric oxide synthase by amino acids and dipeptides
US6803486B2 (en) * 2001-06-22 2004-10-12 Northwestern University Selective neuronal nitric oxide synthase inhibitors
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US6803470B2 (en) * 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
CA2538339A1 (en) * 2003-09-08 2005-03-24 Northwestern University Heteroaromatic selective inhibitors of neuronal nitric oxide synthase

Also Published As

Publication number Publication date
WO2006087577A3 (en) 2006-10-19
WO2006087577A2 (en) 2006-08-24
CA2598484A1 (en) 2006-08-24
US20080070952A1 (en) 2008-03-20
SG160342A1 (en) 2010-04-29
EP1850838A2 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
Olanow et al. A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease
TWI353835B (en) Novel methods for identifying improved, non-sedati
AU2012333092B2 (en) Synergistic combinations of PI3K- and MEK-inhibitors
US20080234310A1 (en) Methods and Compositions for Slowing Aging
ES2765200T3 (es) Tratamiento de efectos secundarios de trastornos motores y de movimiento asociados a tratamientos de la enfermedad de Parkinson
KR20160147044A (ko) 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
US20070179174A1 (en) Methods and compositions for slowing aging
JP2013056911A (ja) 運動障害の予防および／または治療剤
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
US20240016790A1 (en) Methods of using a phenoxypropylamine compound to treat pain
CA3100792A1 (en) Methods and compositions for treatment of alzheimer's disease
EP0980260A1 (en) Pharmaceutical composition comprising at least tyrosine and an iron compound for treating parkinson's disease or depression
EP2213290A1 (en) Agent for improving motor complications or psychiatric symptoms in parkinson's disease
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
JP2015505563A (ja) 姿勢安定性の改善およびドロキシドパの投与
KR20120103557A (ko) 파킨슨씨병 치료용 조성물 및 치료방법
KR20180058659A (ko) 에베롤리무스와 닥톨리십의 약제학적 병용물
JP2008545616A (ja) ジスキネジーの阻害または治療
US11191758B2 (en) Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
US20080318926A1 (en) Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
KR20090031908A (ko) Ｓｌｖ308 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090219

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110221